Press Releases

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
Presented at ASH Annual Meeting Lausanne, Switzerland, December 11, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
Presented at ASH Annual Meeting Lausanne, Switzerland, December 11, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting
Lausanne, Switzerland, November 15, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that five abstracts, including one oral presentation, have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting taking place

ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials

ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials
Lausanne, Switzerland, October 23, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $200 million through a private placement. The financing was oversubscribed and supported by both existing and new investors, including

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma
- First clinical data of ADCT-402 demonstrate encouraging antitumor activity in relapsed or refractory non-Hodgkin’s lymphoma Lausanne, Switzerland, June 16, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the first clinical data from an

ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML

ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML
- Favorable tolerability and efficacy results of ADCT-301 in extensively pretreated patients Lausanne, Switzerland, June 16, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the interim data from an ongoing Phase I clinical trial

ADC Therapeutics will be attending the 14th International Conference on Malignant Lymphoma June 14-17, 2017 in Lugano, Switzerland

ADC Therapeutics will be attending the 14th International Conference on Malignant Lymphoma June 14-17, 2017 in Lugano, Switzerland
ADC Therapeutics will be attending the 14th International Conference on Malignant Lymphoma that will take place in the Lugano Convention Centre www.lymphcon.ch. The abstracts for an oral presentation (ADCT-402) can be downloaded under this link and for a poster (ADCT-301) under this link. For more information please contact: Investors Contact Dr. Chris Martin Chief Executive

ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Lausanne, Switzerland, June 9, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADCT-402 for the treatment of diffuse large B-cell lymphoma

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression
- Trial to provide data on safety, tolerability, pharmacokinetics and efficacy - ADCT-502 represents ADC Therapeutic’s fourth ADC program in clinical trials Lausanne, Switzerland, May 19, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that

ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting

ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting
Lausanne, Switzerland, March 30, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2017 taking place April 1-5, 2017 in